Adalimumab BS MA
Adalimumab biosimilar developed by Mochida Pharmaceutical. Reference product Humira.
About Adalimumab BS MA
Adalimumab BS MA is Mochida's adalimumab, approved in Japan in March 2021 as the third adalimumab biosimilar there. It is offered in the high-concentration form, in three strengths as a syringe and one as a pen, with a full set of Japanese indications. Mochida is a mid-sized Japanese company with several biosimilars in its range, including etanercept, teriparatide, pegfilgrastim and tocilizumab.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan · Adalimumab BS MA
Pharmaceuticals and Medical Devices Agency and MHLWApprovedCanada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Adalimumab BS MA holds an approval, these are the other adalimumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| PMDA | 3 | Celltrion (Yuflyma), Daiichi Sankyo (Adalimumab BS Daiichi Sankyo), Fujifilm Kyowa Kirin Biologics (Hulio) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Mochida Pharmaceutical: Etanercept BS MA, Pegfilgrastim BS Mochida / Nipro, Teriparatide BS Mochida, Tocilizumab BS MA.
Chronology
- PMDAMar 2021Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning adalimumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant